
NYSEHealthcareMedical - Diagnostics & Research
ข้อมูลล่าสุด
US$168.17
−US$0.92 · -0.54%
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
ราคาปิดก่อนหน้า
US$168.17
−US$0.92 · -0.54%
ก่อนเปิดตลาด
US$168.56
+US$0.39 · +0.23%
9 ต.ค. 7:16 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
ช่วงราคารายวัน
ปัจจุบัน US$168.17
ช่วง 52 สัปดาห์
ปัจจุบัน US$168.17
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
86
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
61
เชิงบวก
ความเสี่ยง
49
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
48
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
ช่วงราคารายวัน
ปัจจุบัน US$168.17
ช่วง 52 สัปดาห์
ปัจจุบัน US$168.17
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 6.95B USD | 6.51B USD | 6.83B USD | 6.85B USD | 6.32B USD |
| ต้นทุนสินค้าขาย | 3.31B USD | 2.98B USD | 3.37B USD | 3.13B USD | 2.91B USD |
| กำไรขั้นต้น | 3.64B USD | 3.54B USD | 3.47B USD | 3.72B USD | 3.41B USD |
| การวิจัยและพัฒนา | 455M USD | 479M USD | 481M USD | 467M USD | 441M USD |
| การขาย ทั่วไป และธุรการ | 1.71B USD | 1.52B USD | 1.63B USD | 1.64B USD | 1.62B USD |
| ค่าใช้จ่ายในการดำเนินงาน | 2.16B USD | 2.05B USD | 2.12B USD | 2.1B USD | 2.06B USD |
| รายได้ดอกเบี้ย | 62M USD | 80M USD | 51M USD | 9M USD | 2M USD |
| ดอกเบี้ยจ่าย | 112M USD | 96M USD | 95M USD | 84M USD | 81M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 288M USD | 257M USD | 271M USD | 317M USD | 321M USD |
| รายได้จากการดำเนินงาน | 1.48B USD | 1.49B USD | 1.35B USD | 1.62B USD | 1.35B USD |
| รายได้สุทธิ | 1.3B USD | 1.29B USD | 1.24B USD | 1.25B USD | 1.21B USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 9 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
| รายการ | วันที่มีผลบังคับใช้ | รายละเอียด | วันกำหนดรายชื่อ | วันจ่ายเงิน |
|---|---|---|---|---|
การแยกหุ้น | 3 พ.ย. 2557 | 699:500 | — | — |
มีผลแล้ว 3 พ.ย. 2557
699:500
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
State Street SPDR S&P 500 ETF1557.T92.3B0.07%129.69T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI1.38B0.06%2.3T USD0.03%US$379.56-0.39%
Vanguard S&P 500 ETFVOO1.15B0.07%1.8T USD0.03%US$711.28-0.43%
Vanguard Morningstar Mid-Cap ETFVO937.41M0.41%226.4B USD0.03%US$80.40+0.32%
iShares Core S&P 500 ETFIVV635.44M0.07%897.2B USD0.03%US$777.27-0.42%
State Street SPDR S&P 500 ETFSPY583.5M0.07%821.54B USD0.09%US$773.93-0.42%
Vanguard Morningstar Value ETFVTV414.05M0.16%262.4B USD0.03%US$219.63+0.65%
State Street Health Care Select Sector SPDR ETFXLV335.37M0.78%43.48B USD0.08%US$168.16-0.39%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLVเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน